Welcome to our dedicated page for Zimmer Biomet Holdings news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet Holdings stock.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) is a preeminent global leader in musculoskeletal healthcare. Headquartered in Warsaw, Indiana, Zimmer Biomet has been at the forefront of advancing bone and joint health for nearly 90 years. The company designs, manufactures, and markets a comprehensive range of orthopedic implants and surgical equipment, addressing joint reconstruction, bone repair, sports medicine, spine, and dental reconstruction. Its innovative product portfolio includes the ROSA® Robotics systems for knee, hip, and shoulder replacements, and the TMINI Miniature Robotic System for total knee arthroplasty.
Zimmer Biomet's latest endeavors include the establishment of a dedicated Health Equity division in 2023, which aims to integrate health equity into the company's core strategies and operations. This division has already made significant strides by assembling a strategic advisory board and developing the Community Centered Care (C3) framework to increase patient access to quality care in underserved communities.
In addition, Zimmer Biomet has recently partnered with top pickleball organizations in the U.S., underscoring its commitment to joint health and well-being for the growing community of pickleball players. The company also announced a strategic alliance with CBRE Group, Inc. to expand orthopedic ambulatory surgery centers across the country, and a collaboration with RevelAi Health to commercialize AI-powered engagement solutions aimed at advancing value-based orthopedic care and health equity.
Financially, Zimmer Biomet has demonstrated robust performance, with first-quarter 2024 net sales amounting to $1.889 billion, a 3.2% year-over-year increase. The company continues to focus on innovation, operational excellence, and strategic partnerships to drive growth and enhance shareholder value. For more information, visit www.zimmerbiomet.com or follow them on LinkedIn and Twitter.
Zimmer Biomet Holdings reported first-quarter net sales of $1.847 billion, a 3.6% increase year-over-year, and net earnings of $198.1 million. Diluted EPS stood at $0.94, with adjusted EPS at $1.71, reflecting a 0.6% rise from the previous year. The company expects a continued positive trend as elective procedures resume post-pandemic. Key highlights include the launch of ZBEdge technologies and FDA clearance for the ROSA® Partial Knee System, alongside leadership appointments aiding in their ongoing transformation.
ZBH announced that President and CEO Bryan Hanson and Executive VP and CFO Suky Upadhyay will present at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 12:30 p.m. ET. The live webcast will be accessible via Zimmer Biomet's Investor Relations website and archived for replay afterward. Founded in 1927, Zimmer Biomet is a leader in musculoskeletal healthcare, providing orthopedic and surgical products globally. The company operates in over 25 countries and sells in more than 100 countries.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) announced FDA 510(k) clearance for the ROSA® Partial Knee System, which enhances robotically-assisted partial knee replacement surgeries. This addition to Zimmer Biomet's ROSA Robotics platform aims to improve patient outcomes and surgical accuracy. The system leverages advanced imaging technology and intraoperative data collection, which can optimize surgery based on individual patient anatomy. With over 50% of the global partial knee market share, Zimmer Biomet continues to lead in musculoskeletal healthcare, emphasizing its commitment to innovative solutions.
Zimmer Biomet Holdings (ZBH) will host its first quarter earnings conference call on May 4, 2021, at 8:30 a.m. ET. An associated news release with financial results will be available earlier that day at 6:30 a.m. ET. The conference call can be accessed via Zimmer Biomet's Investor Relations website, with a digital recording available post-call until July 6, 2021. This call provides an opportunity for investors to evaluate the company's financial performance and future outlook.
Zimmer Biomet Holdings (NYSE: ZBH) launched the ZBEdge™ Connected Intelligence Suite, featuring advanced digital and robotic technologies aimed at enhancing patient outcomes. Key components include the ROSA® Robotics Platform, Signature™ ONE Surgical Planning, and mymobility® with Apple Watch®. This suite integrates pre-, intra-, and post-operative technologies, leveraging data for improved surgical insights. The initiative underscores Zimmer Biomet's commitment to optimizing the patient experience and empowering healthcare professionals through actionable data.
Zimmer Biomet Holdings, Inc. (ZBH) announced important changes in its Executive Leadership Team on March 31, 2021. Lori Winkler has been appointed as the Chief Human Resources Officer (CHRO), having previously served as Group Vice President of Human Resources. Sang Yi has been promoted to Group President for Asia Pacific, a role he has held since June 2015. Both appointments are aimed at strengthening the company's human resources and regional operations as part of its mission to improve patient care globally.
Zimmer Biomet Holdings has appointed Ivan Tornos as Chief Operating Officer, effective March 19, 2021. Tornos, who joined the company in November 2018, will oversee all global businesses and lead operations, clinical education, and R&D. He continues to lead the Americas and now adds the EMEA region to his responsibilities. The company also announced Didier Deltort's departure as President of EMEA, effective immediately, with a search underway for his replacement. Tornos brings extensive experience from Becton, Dickinson, and C.R. Bard.
Zimmer Biomet Holdings has announced a quarterly cash dividend of $0.24 per share for the first quarter of 2021. The dividend is payable on April 30, 2021, to stockholders of record by March 29, 2021. The company continues to lead in musculoskeletal healthcare, providing a range of products for orthopedic reconstruction, sports medicine, and more. With operations in over 25 countries, Zimmer Biomet aims to enhance patient care through innovative solutions.
Zimmer Biomet Holdings announced significant changes to its Board of Directors. Sreelakshmi Kolli, Chief Digital Officer at Align Technology, joins the board immediately. Larry C. Glasscock, the Non-Executive Chairman, will retire in May 2021 as per governance guidelines. Following his retirement, Bryan C. Hanson, the current President and CEO, will assume the role of Chairman. Christopher B. Begley will become the Lead Independent Director. Additionally, Gail K. Boudreaux has opted not to seek reelection at the upcoming annual meeting. These changes reflect Zimmer Biomet's ongoing strategic initiatives.
Zimmer Biomet Holdings (NYSE: ZBH) announced that President and CEO Bryan Hanson and CFO Suky Upadhyay will present at the Cowen 41st Annual Health Care Conference on March 4, 2021, at 11:10 a.m. ET. The presentation will be accessible via a live webcast on Zimmer Biomet's Investor Relations website and will be archived for replay.
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a leader in musculoskeletal healthcare, providing innovative orthopedic and surgical products worldwide.
FAQ
What is the current stock price of Zimmer Biomet Holdings (ZBH)?
What is the market cap of Zimmer Biomet Holdings (ZBH)?
What does Zimmer Biomet do?
Where is Zimmer Biomet headquartered?
What are Zimmer Biomet's latest innovations?
What is Zimmer Biomet's focus on health equity?
How did Zimmer Biomet perform financially in the first quarter of 2024?
What are Zimmer Biomet's partnerships?
What is the ROSA® Robotics system?
What is the Community Centered Care (C3) framework?
What is Zimmer Biomet's role in pickleball?
How does Zimmer Biomet contribute to innovation in healthcare?
